Table 2.
Individual change scores in FACT-ES
| Subject | Change in scores after 3 months of dose reduction |
||
|---|---|---|---|
| HR-QOL | Endocrine subscale 19 | Endocrine subscale 23 | |
| 1 | 18 | 23 | 26 |
| 2 | 2 | −1 | −3 |
| 3 | 11 | 3 | 2 |
| 4 | −6 | 2 | 5 |
| 5 | 19 | 9 | 6 |
| 6 | 6 | 1 | 1 |
| 7 | 16 | 21 | 24 |
| 8 | −5 | −3 | −2 |
| 9 | 45 | 14 | 23 |
| 10 | 18 | 10 | 11 |
| 11 | −4 | 1 | 0 |
| 12 | 5 | 7 | 6 |
| 13 | −21 | −12 | −13 |
| 14 | 8 | −2 | 1 |
| 15 | 9 | −9 | −7 |
| 16 | 12 | 30 | 36 |
| 17 | 6 | 3 | 4 |
| 0.5 SD | 5.65 | 5.35 | 6.05 |
Change in scores of FACT-ES questionnaire after 3 months of tamoxifen dose reduction compared to FACT-ES scores at steady-state tamoxifen 20 mg. Negative change scores stand for worsening of symptoms, while positive change scores stand for improvement of symptoms. Change scores of >0.5 baseline SD are considered clinically relevant.
FACT-ES, Functional Assessment of Cancer Therapy—Endocrine Symptoms; HR-QOL, health-related quality of life; SD, standard deviation.